{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:55:10Z","timestamp":1790517310365,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,9,26]],"date-time":"2003-09-26T00:00:00Z","timestamp":1064534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1007\/s00430-003-0201-2","type":"journal-article","created":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T10:38:29Z","timestamp":1079779109000},"page":"173-180","source":"Crossref","is-referenced-by-count":72,"title":["Miltefosine (Impavido): the first oral treatment against leishmaniasis"],"prefix":"10.1007","volume":"193","author":[{"given":"H.","family":"Sindermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Eibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,9,26]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0166-6851(87)90146-0","volume":"23","author":"Achterberg","year":"1987","unstructured":"Achterberg V, Gercken G (1987) Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastogotes. Mol Biochem Parasitol 23:117?122","journal-title":"Mol Biochem Parasitol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0166-6851(87)90080-6","volume":"26","author":"Achterberg","year":"1987","unstructured":"Achterberg V, Gercken G (1987) Metabolism of ether lyophospholipids in Leishmania donovani promastigotes. Mol Biochem Parasitol 26:277?287","journal-title":"Mol Biochem Parasitol"},{"key":"CR3","first-page":"85","volume":"2","author":"Berman","year":"1991","unstructured":"Berman JD (1991) Biological mechanisms of clinical antileishmanial agents: a review. J Cell Pharmacol 2:85?82","journal-title":"J Cell Pharmacol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clind\/24.4.684","volume":"24","author":"Berman","year":"1997","unstructured":"Berman JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684?703","journal-title":"Clin Infect Dis"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0035-9203(85)90197-X","volume":"79","author":"Bryceson","year":"1985","unstructured":"Bryceson ADM, Chulay JD, Ho M, Mugambii M, Were JB (1985) Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg 79:700?704","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR6","unstructured":"Bryceson ADM (1987) Therapy in man. In: Peters W, Killick-Kendrick R (eds) The leishmaniasis in biology and medicine, Vol 2. Academic Press, New York, pp 848?907"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1515\/znb-1964-1207","volume":"19B","author":"Burdzy","year":"1964","unstructured":"Burdzy K, Munder PG, Fischer H, Westphal O (1964) Steigerung der Phagozytose von Perionialmagrophagen durch Lysolecithin. Z Naturforsch 19B:1118","journal-title":"Z Naturforsch"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","volume":"36","author":"Croft","year":"1987","unstructured":"Croft SL, Neal RA, Pendergast W, Chan JH (1987) The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 36:2633?2636","journal-title":"Biochem Pharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0035-9203(93)90499-G","volume":"87","author":"Croft","year":"1993","unstructured":"Croft SL, Neal RA, Thornton E, Herrmann DBJ (1993) Antileishmanial activity of the ether phospholipid ilmofosine. Trans R Soc Trop Med Hyg 87:217?219","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jac\/38.6.1041","volume":"38","author":"Croft","year":"1996","unstructured":"Croft SL, Snowdon D, Yardley V (1996) The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38:1041?1047","journal-title":"J Antimicrob Chemother"},{"key":"CR11","first-page":"75","volume":"87","author":"Davidson","year":"1994","unstructured":"Davidson RN, Di Martino L, Gradoni L, Giacchino R (1994) Liposomal amphotericin B (Am Bisome) in Mediteranian visceral leishmaniasis: a multicenter trial. Q J Med 87:75?81","journal-title":"Q J Med"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00003495-199856060-00005","volume":"56","author":"Davidson","year":"1998","unstructured":"Davidson RN (1998) Practical guide for the treatment of leishmaniasis. Drug 56:1009?1018","journal-title":"Drug"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0738-081X(96)00057-0","volume":"14","author":"Desjeux","year":"1996","unstructured":"Desjeux P (1996) Leishmaniasis: public health aspects and control. Clin Dermatol 14:417?423","journal-title":"Clin Dermatol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/clinids\/17.6.981","volume":"17","author":"Dietze","year":"1993","unstructured":"Dietze R, Milan EP, Berman JD, Grogl M (1993) Treatment of Brazilian Kala-Azar with a short course of Amphocil (Amphotericin B-chlolesterol dispersion). Clin Infect Dis 17:981?986","journal-title":"Clin Infect Dis"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0035-9203(91)90025-T","volume":"85","author":"Dogra","year":"1991","unstructured":"Dogra J (1991) A double-blind study on the efficacy of oral Dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 85:212?213","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1128\/AAC.45.6.1872-1875.2001","volume":"45","author":"Escobar","year":"2001","unstructured":"Escobar P, Yardley V, Croft SL (2001) Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45:1872?1875","journal-title":"Antimicrob Agents Chemother"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0001-706X(01)00197-8","volume":"81","author":"Escobar","year":"2002","unstructured":"Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81:151?157","journal-title":"Acta Trop"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0035-9203(94)90309-3","volume":"88","author":"Gokhale","year":"1994","unstructured":"Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK (1994) Successful treatment of resistant visceral Leishmaniasis with liposomal Amphotericin B. Trans R Soc Trop Med Hyg 88:228","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0190-9622(96)80121-6","volume":"34","author":"Grevelink","year":"1996","unstructured":"Grevelink SA, Lerner EA (1996) Leishmaniasis. J Am Acad Dermatol 34:257?272","journal-title":"J Am Acad Dermatol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0014-4894(89)90173-2","volume":"69","author":"Grogl","year":"1989","unstructured":"Grogl M, Oduola AMJ, Cordero LDC, Kyle DE (1989) Leishmania spp: development of Pentostam resistant clones in vitro by discontinuous drug exposure. Exp Parasitol 69:78?90","journal-title":"Exp Parasitol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/jir.1993.13.39","volume":"13","author":"Harms","year":"1993","unstructured":"Harms G, Zwingenberger K, Sandkamp B, Omena S, Pedrosa C, Richter J, Rosenkaimer F (1993) Immunochemotherapy of visceral leishmaniasis. A pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony. J Interferon Res 13:39?41","journal-title":"J Interferon Res"},{"key":"CR22","first-page":"465","volume":"87","author":"Hepburn","year":"1994","unstructured":"Hepburn NC, Nolan J, Fenn L, Herd RM, Neilson JMM (1994) Cardiac effects of sodium stibogluconate. Q J Med 87:465?472","journal-title":"Q J Med"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1056\/NEJM199912093412411","volume":"341","author":"Herwaldt","year":"1999","unstructured":"Herwaldt BL (1999) Miltefosine?the long-awaited therapy for visceral leishmaniasis? N Engl J Med 341:1840?1842","journal-title":"N Engl J Med"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0277-5379(88)90336-7","volume":"24","author":"Hilgard","year":"1988","unstructured":"Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl HJ, Unger C, Berger MR (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D-18506). Eur J Cancer Clin Oncol 24:1457?1461","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF01612758","volume":"117","author":"Hilgard","year":"1991","unstructured":"Hilgard P, Kampherm E, Nolan L, Pohl J, Reissmann T (1991) Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J Cancer Res Clin Oncol 117:403?408","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0008-8749(92)90135-C","volume":"141","author":"Hochhuth","year":"1992","unstructured":"Hochhuth CH, Vehmeyer K, Eibl HJ, Unger C (1992) Hexadecylphosphocholine induces interferone-? secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 141:161?168","journal-title":"Cell Immunol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4269\/ajtmh.1995.52.536","volume":"52","author":"Jha","year":"1995","unstructured":"Jha TK, Giri YN, Singh TK, Jha S (1995) Use of amphotericin B in drug resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Med Hyg 52:536?538","journal-title":"Am J Trop Med Hyg"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","volume":"341","author":"Jha","year":"1999","unstructured":"Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795?1800","journal-title":"N Engl J Med"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-4899-0179-8_30","volume":"416","author":"Klenner","year":"1996","unstructured":"Klenner T, Beckers T, Nooter K, Holtmann H (1996) Influence of hexadecylphosphocholine (Miltefosine) on cytokine synthesis and biological responses. Adv Exp Med Biol 416:181?187","journal-title":"Adv Exp Med Biol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.36.8.1630","volume":"36","author":"Kuhlencord","year":"1992","unstructured":"Kuhlencord A, Maniera T, Eibl H, Unger C (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36:1630?1634","journal-title":"Antimicrob Agents Chemother"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.42.3.654","volume":"42","author":"Le","year":"1998","unstructured":"Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D, Kubar J (1998) Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB\/c mice. Antimicrob Agents Chemother 42:654?658","journal-title":"Antimicrob Agents Chemother"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1086\/314896","volume":"180","author":"Lira","year":"1999","unstructured":"Lira R, Sundar S, Makharia A, et al (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony resistantstrains of Leishmania donovani. J Infect Dis 180:564","journal-title":"J Infect Dis"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/jac\/47.5.537","volume":"47","author":"Lira","year":"2001","unstructured":"Lira R, Contreras LM, Santa-Rita RM, Urbina JA (2001) Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of the in-vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47:537?546","journal-title":"J Antimicrob Chemother"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4899-0179-8_33","volume":"416","author":"Lux","year":"1996","unstructured":"Lux H, Hart DT, Parker PJ, Klenner T (1996) Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for antileishmanial alkyl phospholipid analogues. Adv Exp Med Biol 416:201?211","journal-title":"Adv Exp Med Biol"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(00)00278-4","volume":"111","author":"Lux","year":"2000","unstructured":"Lux H, Heise N, Klenner T, Hart D, Opperdoes FR (2000) Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 111:1?14","journal-title":"Mol Biochem Parasitol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/clinids\/19.2.362","volume":"19","author":"McBride","year":"1994","unstructured":"McBride M, Linney M, Claydon EJ, Weber J (1994) Visceral leishmaniasis following treatment with liposomal amphotericin B. Clin Infect Dis 19:362","journal-title":"Clin Infect Dis"},{"key":"CR37","unstructured":"Murray HW, Squires KE, Harms G, Rosenkaimer F (1992) Clinical trials of interferon-gamma for leishmaniasis. In: Sonnenfeld G, Czarniecki C, Nacy C, et al (eds) Cytokines and resistance to nonviral infections. Biomedical Press, Augusta, pp 199?206"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1128\/AAC.44.11.3235-3236.2000","volume":"44","author":"Murray","year":"2000","unstructured":"Murray HW (2000) Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 44:3235?3236","journal-title":"Antimicrob Agents Chemother"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/315268","volume":"181","author":"Murray","year":"2000","unstructured":"Murray HW, Delph-Etienne S (2000) Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 181:795?799","journal-title":"J Infect Dis"},{"key":"CR40","first-page":"37","volume":"17","author":"Safa","year":"1997","unstructured":"Safa O, Parkin SM, Matthew AM, Bibby MC (1997) Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res 17:37?44","journal-title":"Anticancer Res"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0001-706X(00)00052-8","volume":"75","author":"Santa-Rita","year":"2000","unstructured":"Santa-Rita RM, Barbosa HS, Meirelles MNSL, Castro SL de (2000) Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 75:219?228","journal-title":"Acta Trop"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0035-9203(99)90192-X","volume":"93","author":"Schmidt-Ott","year":"1999","unstructured":"Schmidt-Ott R, Klenner T, Overath P, Aebischer T (1999) Topical treatment with hexadecylphosphocholine (Miltex\u00ae) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 93:85?90","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1086\/322689","volume":"33","author":"Soto","year":"2001","unstructured":"Soto J, Toledo J, Gutierrez P, Nicholis RS, Padilla J, Engel J, Fischer C, Voss A, Berman J (2001) Treatment of American cutaneous leishmaniasis with Miltefosine, an oral agent. Clin Infect Dis 33:E57?E61","journal-title":"Clin Infect Dis"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4269\/ajtmh.1993.48.666","volume":"48","author":"Squires","year":"1993","unstructured":"Squires KE, Rosenkaimer F, Sherwood JA, Were JBO, Murray HW (1993) Immunochemotherapy for visceral Leishmaniasis. A controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg 48:666?669","journal-title":"Am J Trop Med Hyg"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/infdis\/170.3.659","volume":"170","author":"Sundar","year":"1994","unstructured":"Sundar S, Rosenkaimer F, Murray HW (1994) Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis 170:659?662","journal-title":"J Infect Dis"},{"key":"CR46","doi-asserted-by":"crossref","unstructured":"Sundar S, Rosenkaimer F, Lesser ML, Murray HW (1995) Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis J Infect Dis 171:992?996","DOI":"10.1093\/infdis\/171.4.992"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","volume":"352","author":"Sundar","year":"1998","unstructured":"Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW (1998) Trial of miltefosine for visceral leishmaniasis. Lancet 352:1821?1823","journal-title":"Lancet"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00034983.1999.11813462","volume":"93","author":"Sundar","year":"1999","unstructured":"Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW (1999) Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93:589?597","journal-title":"Ann Trop Med Parasitol"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/318122","volume":"31","author":"Sundar","year":"2001","unstructured":"Sundar S, Makharia A, More DK, Agraval G, Voss A, Fischer C, Bachmann P, Murray HW (2001) Short course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 31:1110?1113","journal-title":"Clin Infect Dis"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","volume":"347","author":"Sundar","year":"2002","unstructured":"Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739?1746","journal-title":"N Engl J Med"},{"key":"CR51","first-page":"434","volume":"22","author":"Sundar","year":"2003","unstructured":"Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J (2003) Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 22:434?438","journal-title":"Pediatr Infect Dis J"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0035-9203(94)90106-6","volume":"88","author":"Teklemariam","year":"1994","unstructured":"Teklemariam S, Hiwot AG, Frommel D, Miko TL (1994) Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88:334?339","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR53","first-page":"103","volume":"92","author":"Thakur","year":"1991","unstructured":"Thakur CP, Kumar M, Pandey AK (1991) Evaluation of efficacy of longer durations of therapy for fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 92:103?120","journal-title":"Indian J Med Res"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0035-9203(92)90150-B","volume":"86","author":"Thakur","year":"1992","unstructured":"Thakur CP, Olliaro P, Gothoskar S, Bhowmick S (1992) Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycine)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 86:615?616","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1248\/cpb.30.3260","volume":"Bull","author":"Tsushima","year":"1982","unstructured":"Tsushima S, Yoshioka Y, Tanida S, Nomura H, Nojima S, Hozumi M (1982) Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem Pharm Bull (Tokyo) 30:3260?3270","journal-title":"Chem Pharm"},{"key":"CR56","first-page":"133","volume":"34","author":"Unger","year":"1998","unstructured":"Unger C, Maniera T, Kaufmann-Kolle P, Eibl H (1998) In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 34 (Suppl F):133?140","journal-title":"Drugs Today"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/BF01211805","volume":"118","author":"Verweij","year":"1992","unstructured":"Verweij J, Plating A, Berg M van der, Stoter G (1992) A dose finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J Cancer Res Clin Oncol 118:606?608","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR58","unstructured":"Wilcocks C, Manson-Bahr PEC (1972) Manon's tropical diseases. Bailli\u00e8re Tindall, London, pp 119?133"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-003-0201-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00430-003-0201-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-003-0201-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:11:37Z","timestamp":1559067097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-003-0201-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,26]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1007\/s00430-003-0201-2","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,26]]}}}